{"id":"NCT05408429","sponsor":"Pfizer","briefTitle":"Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13","officialTitle":"A PHASE 3, RANDOMIZED, PARTIALLY DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY TODDLERS 12 THROUGH 23 MONTHS OF AGE WITH 2 PRIOR INFANT DOSES OF PREVENAR 13","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-06-24","primaryCompletion":"2023-06-01","completion":"2023-06-01","firstPosted":"2022-06-07","resultsPosted":"2024-09-19","lastUpdate":"2024-09-19"},"enrollment":356,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"20-valent pneumococcal conjugate vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"13-valent pneumococcal conjugate vaccine","otherNames":[]}],"arms":[{"label":"2-Dose 20vPnC Group","type":"EXPERIMENTAL"},{"label":"1-Dose 20vPnC Group","type":"EXPERIMENTAL"},{"label":"13vPnC Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in toddlers who had 2 prior doses of Prevnar 13.\n\nThis study is being conducted in children who:\n\n* are between 12 to 23 months of age;\n* are healthy as determined by the study doctors;\n* have received 2 doses of Prevnar 13 during the first year in life.\n\nParticipants in this study will receive either 1 dose or 2 doses of the study vaccine or 1 dose of Prevnar 13 as a shot in the muscle. During the study, participants will have to come to the study clinic to receive the vaccines and have blood sample collected. The study team will work with participants' parents or legal guardians to monitor any unwanted reactions to the vaccines. Participants are expected to take part in this study for about 1 or 3 months, for 1 dose or 2 dose schedules, respectively.","primaryOutcome":{"measure":"Percentage of Participants With Local Reactions Within 7 Days After Last Vaccination","timeFrame":"Within 7 days after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)","effectByArm":[{"arm":"2-Dose 20vPnC","deltaMin":26.3,"sd":18.5},{"arm":"1-Dose 20vPnC","deltaMin":29.7,"sd":21.6},{"arm":"13vPnC Control","deltaMin":32.5,"sd":24.1}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":43,"countries":["Hungary","Poland","Spain"]},"refs":{"pmids":["40081152"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B7471027"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":121},"commonTop":["Irritability","Injection site erythema (REDNESS)","Hypersomnia (INCREASED SLEEP)","Injection site pain (PAIN)","Decreased appetite (DECREASED APPETITE)"]}}